Skip to main content
FWA
Future WorkAcademy
In active development — Fall 2026 pilot
Ankeny, Iowa · Iowa Medtech Corridor · ISO 13485 / FDA Class III Ready

Iowa is not just farm equipment. Heartland is set in the Des Moines metro medtech corridor — cleanrooms, FDA registration, and supplier-quality scorecards.

Iowa Medtech Manufacturing Simulation

Heartland Micromolding
Ankeny, Iowa

Step into the Chief Operating Officer seat at a 250-person, family-owned specialty micro injection molder serving the medical-device, microelectronics, and automotive-sensor industries. Iowa is not just farm equipment — and this simulation proves it.

Platform: ready today

The simulation engine, AI grading, instructor tooling, dashboards, and Privacy Mode enrollment that power Apex are the same technology that will run Heartland. Iowa medtech and community-college partners can preview the experience now using the flagship simulation.

Content: in development

The canonical seed, eight-week scenario arc, 14-stakeholder cast, dual-rubric scoring (Financial 50% / Cultural 50%) tuned for medical-device manufacturing, and the FDA / ISO 13485 / IEDA citation library are authored. Pilot launch: Fall 2026.

The Scenario

Ankeny, Iowa. Class 7 cleanrooms. Tolerances in microns. A founder who built it in a garage.

Heartland Micromolding, Inc. is a 250-person, family-owned specialty micro injection molder founded in Ankeny, Iowa in 1982 — at the heart of the Iowa / Midwest medtech corridor. Roughly 60% of revenue is medical devices — catheter components, drug-delivery, diagnostics — manufactured in ISO Class 7 and Class 8 cleanrooms under ISO 13485:2016 and FDA registration. The other 40% is microelectronics and automotive sensors. Annual revenue is approximately $78M. EBITDA margin sits near 16.5%.

Your largest medtech customer — about 28% of revenue — is consolidating its molding-supplier roster from 14 to 6. They want a 12% price reduction over 24 months, evidence of FDA 21 CFR Part 820 Design Controls maturity on a new Class III catheter component within 9 months, and a documented dual-source supply plan. A coastal private-equity firm has begun circling. The founding family is split on selling, recapitalizing, or staying independent.

You are the new COO. You have six weeks of relationship capital, no equity yet, and eight weeks of decisions ahead of you.

250
Employees
$78M
Annual revenue
28%
Top medtech customer
8
Week arc

Iowa Medtech Context

The Iowa / Midwest medtech corridor — in a simulation.

Regulatory readiness context

  • FDA 21 CFR Part 820 Quality System Regulation — mock inspection in Week 5
  • ISO 13485:2016 — medical device quality management; CAPA closure tracked in scoring
  • FDA Class III catheter component readiness window — 9 months
  • • Supplier-quality scorecard dynamics with medtech OEM Cardia Vascular Systems

Iowa medtech workforce & location

  • Ankeny, Iowa — Des Moines metro; Iowa medtech corridor hub
  • • DMACC Industrial Tech program as cleanroom-technician pipeline (Week 4)
  • Iowa 260F blended training program option for 32-tech ramp in 9 months
  • • IEDA Senior PM as a stakeholder (Iowa talent pipeline and grant alignment)

Why this exists

Iowa is not just farm equipment.

Apex puts students in a Fortune-500 frame. Prairie puts them in a small-town, family-owned ag-equipment supplier with a UAW local. Both are true Iowa stories — and both reinforce, accidentally, that Iowa manufacturing is heavy iron and farm country.

Iowa is also home to a quiet medtech and microelectronics manufacturing base — the kind of work that is performed in cleanrooms, audited by the FDA, and held to tolerances measured in microns. Heartland Micromolding is a fictionalized composite of that ecosystem, set in Ankeny — Des Moines metro — and built around the dynamics that actually break or make a specialty medtech supplier: customer consolidation, regulatory readiness, family ownership, and coastal capital.

Heartland teaches the same leadership skills as Apex and Prairie, but in a world where a single CAPA can lose a customer, a single FDA inspection can pause a line, and a single private-equity meeting can split a family.

Eight-Week Arc

The decisions you'll lead through.

Week 1
The Consolidation Letter
Top medtech customer (~28% of revenue) is cutting its molding-supplier roster from 14 to 6 — and demanding 12% off.
Week 2
The Capital Decision
$3.8M full cleanroom build, $1.6M phased reconfiguration, $600K toll-mold first, or decline the Class III program.
Week 3
The PE Approach
A coastal private-equity firm wants a confidential meeting at 11x EBITDA. Two of three trust beneficiaries quietly want liquidity.
Week 4
The Talent Crunch
Stand up 32 cleanroom techs in 9 months — DMACC academy, external hires, contract bridge, or 260F-blended program.
Week 5
FDA Readiness & a CAPA Near-Miss
Mock 21 CFR Part 820 inspection lands the same day a contained microelectronics CAPA divides quality and engineering.
Week 6
Pricing & the Counter-Offer
Cardia counters at 8% over 24 months, five-year preferred-supplier — and a non-starter IP-access clause.
Week 7
The Cleanroom Contamination Crisis
4:42 a.m. particulate excursion in the validation cleanroom. Operators report eye irritation. The Register has the tip.
Week 8
The Long Game
Sell at 9.5x EBITDA, recapitalize, ESOP transition over seven years, or stay private with organic growth only.

Three Tracks

Apex, Prairie, or Heartland — three Iowa worlds, the same pedagogy.

 ApexPrairieHeartland
IndustryAutomotive partsAg-equipment precision componentsMedical-device specialty micro injection molding
SettingDes Moines, urbanMillbrook, IA — pop. 4,200Ankeny, IA — Des Moines metro
Company size2,400 employees340 employees250 employees
Player roleCEOVP of OperationsChief Operating Officer (COO)
OwnershipCorporateFamily-owned (third generation)Family-owned (founder-led, 1982)
WorkforceNational UAWLocal UAW (Local 847)Non-union (employee council)
Regulatory frameGenericIowa 260F & Manufacturing 4.0FDA 21 CFR Part 820 + ISO 13485
Central tensionAI transformation under debt covenants15% cost ultimatum from #1 customerMedtech customer consolidation + FDA Class III + PE offer

Built for Iowa medtech

FDA-aware. ISO 13485-aware. DMACC- and IEDA-aware.

14 stakeholders, dual-rubric scoring

  • • Founder, family CEO, VP Engineering, Director of Quality, Plant Manager, HR Director
  • • Cardia VP Supply Chain & Director of Quality (the customer)
  • • Coastline Capital MD (the PE offer)
  • • DMACC Industrial Tech Dean & IEDA Senior PM (the Iowa pipeline)
  • • Employee Council Rep & Des Moines Register reporter (the floor and the press)
  • • Financial 50% / Cultural 50% rubric tuned for medical-device manufacturing

Real, verifiable citations

  • • 21 CFR Part 820 — FDA Quality System Regulation
  • • ISO 13485:2016 and ISO 14644-1 cleanroom classification
  • • FDA Premarket Approval (PMA) for Class III devices
  • • BLS OES Iowa wage data for molders & technicians
  • • Iowa HQJ program & Iowa Code §260F training grants
  • • DMACC Career Academy, AdvaMed, SelectUSA Medical Technology

Designed for

Who this simulation is built for.

SOC 51-1011
First-Line Supervisors of Production Workers
Supervisors managing production workers, cleanroom techs, and quality discipline in Iowa medtech manufacturing.
SOC 11-1021
General and Operations Managers
Operations leaders navigating capex sequencing, regulatory readiness, and customer-concentration risk at medtech suppliers.
SOC 11-3051
Industrial Production Managers
Production managers responsible for FDA QSR compliance, cleanroom qualification, and CAPA closure in regulated manufacturing environments.

O*NET SOC codes listed for procurement reviewers, state workforce board staff, and 260F program coordinators.

Running a 260F cohort?

Partner with us as a 260F training provider for Iowa medtech workforce programs. We work with DMACC, IEDA-connected programs, and workforce deans across the Iowa medtech corridor to document training outcomes and support reimbursement.

Help us pilot Heartland.

We're partnering with Iowa medtech manufacturers, DMACC, and IEDA to calibrate the FDA / ISO 13485 dynamics, the family-business arc, and the Fall 2026 pilot cohort.